Advertisement

Topics

AstraZeneca Presents Tagrisso® (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases

07:00 EDT 6 Jun 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Tagrisso extended the length of time patients with CNS metastases live without disease worsening or death to 11.7 months and chemotherapy to 5.6 months in the AURA3 trial Evidence of activity in patients with EGFR mutat...

Other Sources for this Article

Media Inquiries
Michele Meixell, +1-302-885-2677
or
Alexandra Engel, +1-302-885-2677

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca Presents Tagrisso® (osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases"

Quick Search
Advertisement
 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...